Oncology

Patients with advanced esophageal squamous cell carcinoma (ESCC) who receive either one or two checkpoint inhibitors along with chemotherapy have significantly improved overall survival than from chemotherapy alone.

Up to 40% of patients undergoing chemotherapy present with cutaneous adverse reactions. Some are so severe they can lead to a pause or reduction in cancer treatment.

Pertuzumab and trastuzumab plus paclitaxel strong survival outcomes in HER2+/HR- early breast cancer. Results from the WSG (West German Study Group)-ADAPT Her2+/HR- trial at the 2021 ASCO conference.

Canadian, American, German and Belgian researchers have developed an artificial intelligence application that has been able to collect and then synthesize for analysis millions of medical data concerning cancer patients followed for a decade.

Active surveillance (AS) is the standard of care for low-risk prostate cancer management worldwide. But how long do patients benefit from AS before they need further treatment

Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who also carry the G12C mutation in the KRAS gene now have the option of newly approved sotorasib.

Availability of Verity-BCG will help overcome years of intravesical BCG shortage, dose rationing and dose reductions.

An overview of advances in using tyrosine kinase inhibitors (TKIs) and immunotherapy for NSCLC